Skip to main
CMPS
CMPS logo

COMPASS Pathways (CMPS) Stock Forecast & Price Target

COMPASS Pathways (CMPS) Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 67%
Buy 27%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Compass Pathways PLC is poised for growth in the mental health treatment sector, driven by the promising clinical efficacy of its psilocybin formulation, COMP360, which has outperformed Spravato in preliminary data, suggesting a potential competitive advantage. The company's approach to treatment-resistant depression (TRD) not only addresses an underserved patient population but also aligns with broader trends and increased governmental focus on mental health initiatives, particularly for conditions like PTSD. With results indicating the potential for sustained response over longer periods, the commercial prospects for COMP360 appear robust, positioning the company to capitalize on an expanding market for psychedelic therapies.

Bears say

Compass Pathways PLC's stock outlook appears negative due to heightened regulatory scrutiny within the psychedelic sector, exemplified by Lykos Therapeutics' recent adverse AdComm and subsequent complete response letter (CRL), which have collectively contributed to a sell-off of stocks in the industry. The risk of potential failures in clinical trials for Compass's proprietary treatment, COMP360, along with concerns about safety setbacks and the possibility of not securing FDA approval, pose significant challenges to investor confidence. Furthermore, low response rates—evidenced by a only ~20% sustained response in key metrics like the MADRS—raise concerns about the efficacy and market viability of the company’s therapeutic approach.

COMPASS Pathways (CMPS) has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 27% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About COMPASS Pathways (CMPS) Forecast

Analysts have given COMPASS Pathways (CMPS) a Strong Buy based on their latest research and market trends.

According to 15 analysts, COMPASS Pathways (CMPS) has a Strong Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

COMPASS Pathways (CMPS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.